论文部分内容阅读
目的:观察α硫辛酸联合贝那普利对早期糖尿病肾病患者尿微量白蛋白排泄率(UAER)与血清超敏C反应蛋白(hsCRP)水平的影响。方法:64例早期糖尿病肾病住院患者随机分成两组,每组32例。A组予贝那普利片10 mg,po,qd;B组在A组基础上加用α硫辛酸600 mg,ivd,qd。疗程均为2周。比较两组患者治疗前后血糖、血脂、UAER、hs-CRP等指标变化。结果:治疗后,两组UAER均较治疗前明显下降(P<0.05),且B组UAER明显低于A组(P<0.05)。治疗后B组hs-CRP水平明显下降(P<0.05),而A组治疗前后差异无统计学意义(P>0.05)。结论:α硫辛酸联合贝那普利可有效治疗早期糖尿病肾病,降低hs-CRP水平,效果优于单独应用贝那普利。
Objective: To observe the effects of α-lipoic acid combined with benazepril on urinary albumin excretion rate (UAER) and serum hsCRP level in patients with early diabetic nephropathy. Methods: Sixty-four inpatients with early stage diabetic nephropathy were randomly divided into two groups (n = 32 in each group). Group A received benazepril tablets 10 mg, po, qd; Group B added α lipoic acid 600 mg, ivd, qd on the basis of group A. The course of treatment is 2 weeks. The changes of blood glucose, blood lipid, UAER and hs-CRP before and after treatment were compared between the two groups. Results: After treatment, the UAER in both groups decreased significantly (P <0.05), and the UAER in group B was significantly lower than that in group A (P <0.05). After treatment, the hs-CRP level in group B decreased significantly (P <0.05), while there was no significant difference in group A before and after treatment (P> 0.05). CONCLUSION: Alpha lipoic acid combined with benazepril is effective in treating early diabetic nephropathy and lowering hs-CRP level, which is superior to benazepril alone.